Skip to main content

Flumazenil

ADVERTISEMENT
Identification
Molecular formula
C15H14F3N3O2
CAS number
78755-81-4
IUPAC name
5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one
State
State

At room temperature, Flumazenil is found in a solid state, typically in the form of a crystalline powder.

Melting point (Celsius)
198.00
Melting point (Kelvin)
471.15
Boiling point (Celsius)
320.00
Boiling point (Kelvin)
593.15
General information
Molecular weight
303.27g/mol
Molar mass
303.2690g/mol
Density
1.4500g/cm3
Appearence

Flumazenil appears as a white to off-white crystalline powder, which is not particularly soluble in water. It is often observed in pharmaceutical formulations as it is used as a medication.

Comment on solubility

Solubility of 5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one

The solubility of 5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one can be quite intriguing due to the complex structure of the compound. Understanding its solubility is essential for various applications, particularly in pharmaceuticals. Here are key points to consider:

  • Polarity: The presence of the dimethylamino group influences the overall polarity of the compound, potentially enhancing its solubility in polar solvents.
  • Solvent Interaction: This compound may exhibit considerable solubility in solvents such as dimethyl sulfoxide (DMSO) or acetonitrile, owing to its functional groups.
  • Hydrophobic Interactions: The trifluoromethyl and aromatic structures can add hydrophobic characteristics, potentially reducing solubility in water.

As with many organic compounds, solubility can be impacted by factors such as:

  1. Temperature: Increased temperatures often lead to greater solubility.
  2. pH Levels: Variations in pH can also alter the solubility profile significantly.
  3. Concentration: The concentration of the solution may change the solubility behavior, primarily due to intermolecular interactions.

In summary, while the solubility of 5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one is influenced by numerous physicochemical factors, it is essential to conduct empirical studies to determine exact solubility characteristics. This compound serves as a reminder of the intricate relationship between structure and solubility in chemical compounds.

Interesting facts

Interesting Facts about 5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one

The compound known as 5-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-11H-benzo[b][1,4]benzodiazepin-6-one is a fascinating example of a benzodiazepine derivative, which plays a significant role in medicinal chemistry. Here are some intriguing insights about this compound:

  • Pharmacological Relevance: Compounds like this one are often investigated for their potential anxiolytic, sedative, and muscle relaxant properties, which can be critical in managing anxiety disorders and sleep disturbances.
  • Structural Complexity: The unique structural features of this molecule, including the benzodiazepine core and the introduction of a trifluoromethyl group, can significantly enhance its biological activity.
  • Dimethylamino Ethyl Side Chain: The presence of the 2-(dimethylamino)ethyl substituent can contribute to improved pharmacokinetic properties, making the compound more effective in modulating the central nervous system.
  • Research Interest: Due to its complexity and potential therapeutic applications, this compound may be a subject of ongoing research in the field of medicinal chemistry to discover new treatment options.

Furthermore, scientists continue to explore the intricate mechanisms of action for such compounds, often aiming to optimize their safety and efficacy profiles. As a result, this compound embodies the rich interplay between chemistry and pharmacology, showcasing how small modifications to molecular structure can lead to profound changes in biological effects.

Synonyms
BRN 0900768
5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-8-trifluoromethyl-
1168-11-2
DTXSID00151521
5-24-04-00139 (Beilstein Handbook Reference)
DTXCID9074012